Three people sought medical treatment for dangerously low blood sugar in the U.S. last year after taking suspected fake versions of Novo Nordisk’s diabetes drug Ozempic, Reuters reports. America’s Poison Centers, formerly known as American Association of Poison Control Centers, said all three U.S. cases of suspected fake Ozempic were reported by the same regional poison control center, and that the FDA was investigating, without providing further details.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NVO:
- Zealand Pharma believes it can compete in weight-loss drug market, FT says
- Novo Nordisk initiated with an Overweight at Morgan Stanley
- GLP-1 Anti-Obesity Drugs: Slim Waistlines, Fat Profits
- Novo Nordisk, Eli Lilly, others raise prices of hundreds of drugs, WSJ reports
- Novo Nordisk price target raised to DKK 800 from DKK 730 at Morgan Stanley